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The HIV-1 accessory protein viral protein R (Vpr) causes G2 arrest and apoptosis in infected cells. We previously
identified the DNA damage–signaling protein ATR as the cellular factor that mediates Vpr-induced G2 arrest and
apoptosis. Here, we examine the mechanism of induction of apoptosis by Vpr and how it relates to induction of G2
arrest. We find that entry into G2 is a requirement for Vpr to induce apoptosis. We investigated the role of the
mitochondrial permeability transition pore by knockdown of its essential component, the adenine nucleotide
translocator. We found that Vpr-induced apoptosis was unaffected by knockdown of ANT. Instead, apoptosis is
triggered through a different mitochondrial pore protein, Bax. In support of the idea that checkpoint activation and
apoptosis induction are functionally linked, we show that Bax activation by Vpr was ablated when ATR or GADD45a
was knocked down. Certain mutants of Vpr, such as R77Q and I74A, identified in long-term nonprogressors, have been
proposed to inefficiently induce apoptosis while activating the G2 checkpoint in a normal manner. We tested the in
vitro phenotypes of these mutants and found that their abilities to induce apoptosis and G2 arrest are
indistinguishable from those of HIV-1NL4–3 vpr, providing additional support to the idea that G2 arrest and apoptosis
induction are mechanistically linked.
Citation: Andersen JL, DeHart JL, Zimmerman ES, Ardon O, Kim B, et al. (2006) HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS
Pathog 2(12): e127. doi:10.1371/journal.ppat.0020127
Introduction
Loss of CD4
þ lymphocytes is a hallmark of progression to
acquired immune deﬁciency syndrome (AIDS). The mecha-
nisms proposed to explain the loss and dysfunction of CD4
þT
cells are multiple and include indirect effects of viral
infection, such as generalized activation of the immune
system, CD8
þ cytotoxic T lymphocyte–mediated killing of
infected cells, as well as direct effects of infection such as
virus budding, and expression of certain viral genes (reviewed
in [1–3]). Analysis of virus dynamics in vivo has revealed that a
signiﬁcant portion of CD4
þ T-cell death is due to virus-
induced cytotoxicity in the infected cells [4–6], and the
estimated half-life of infected lymphocytes is on the order of
2 d (reviewed in [7]). Therefore, studies that seek to under-
stand the molecular and cellular basis of HIV-1–induced
death in T cells are critical toward explaining how immune
deterioration results from HIV-1 infection.
The HIV-1 viral protein R (Vpr) has emerged as a major
proapoptotic gene product (reviewed in [8,9]). In an effort to
characterize the apoptotic signaling cascade induced by Vpr
downstream of the mitochondria, Muthumani et al. [10,11]
demonstrated that Vpr induces apoptosis via the intrinsic
pathway. This pathway is characterized by cytochrome c
release and caspase 9 activation and is triggered in the
absence of death receptor ligation.
Vpr induces a second type of cytopathic effect by blocking
the cell cycle in the G2 phase. We, and others, have previously
shown that Vpr causes activation of the G2 checkpoint
protein, ATR (ataxia and telangiectasia mutated and Rad3
related), a serine/threonine kinase responsive to DNA damage
and replication stress [12–14]. Furthermore, activation of
ATR by Vpr is required for Vpr-induced G2 arrest and
involves the ATR-associated molecules Rad17 and the Rad9-
Rad1-Hus1 trimer [14–16].
A cause–effect relationship between the two deleterious
actions of Vpr (G2 arrest and apoptosis) has not been
established. Indirect evidence supports the notion that
induction of G2 arrest and apoptosis are linked. For example,
treatment of cells with either caffeine, an inhibitor of ATR/
ATM checkpoint function, or small interfering RNA (siRNA)
speciﬁc to ATR, relieves both Vpr-induced G2 arrest and
apoptosis [17,18]. In addition, Yuan et al. [19,20] demon-
strated that siRNA knockdown of Wee1, a Cdk1 inhibitor that
is activated by DNA damage, abrogated both Vpr-induced G2
arrest and apoptosis. Taken together, these data suggest a
model in which checkpoint activation and apoptosis signaling
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association stems from the ability of Vpr to activate ATR
[12–14,17].
On the other hand, evidence from mutagenesis studies
suggests that checkpoint activation and apoptosis may be
separable effects of Vpr. Thus, mutants of Vpr have been
described that induce normal levels of G2 arrest but are
partially impaired for induction of apoptosis [21,22]. One
model to explain the proapoptotic activity of Vpr was
proposed by Jacotot et al. [23] and Vieira et al. [24], who
observed that recombinant Vpr associates with the adenine
nucleotide transporter (ANT) on puriﬁed mitochondria, to
directly promote release of mitochondrion-associated cyto-
chrome c and apoptosis. This ﬁnding suggested that Vpr
initiated the commitment to apoptosis at the mitochondrial
membrane by binding to ANT, rather than by activating
upstream stress signaling pathways derived from checkpoint
activation.
In the present study, we examine the relationship between
induction of G2 arrest and onset of apoptosis by Vpr. We ﬁnd
that entry into G2 is a requirement for Vpr to induce
apoptosis. Since the requirement for entry into G2 seemed
inconsistent with the reported ability of Vpr to bind to ANT
and promote apoptosis in a cell cycle–independent manner,
we then examined the requirement for ANT. We ﬁnd that
Vpr-induced apoptosis is unaffected by knockdown of ANT.
Instead, Vpr-induced apoptosis is dependent on the presence
of Bax and is concomitant with Bax activation. Furthermore,
Bax activation is a result of proapoptotic signals transduced
by Vpr through the upstream stress proteins ATR and
GADD45a (growth arrest and DNA damage–responsive
protein a) because knockdown of ATR or GADD45a
prevented activation of Bax. We also demonstrate that,
despite the striking similarities between the signaling events
induced by Vpr and those induced by genotoxic stress,
important differences can be found. Speciﬁcally, Vpr-
induced apoptosis is abrogated by checkpoint inhibition,
while apoptosis induced by genotoxic agents is exacerbated
by checkpoint inhibition. Taken together, these results
demonstrate that Vpr activates the ATR-initiated DNA
damage–signaling pathway to link checkpoint activation and
commitment to apoptosis.
Results
G2 Arrest Precedes the Release of Mitochondrial Smac and
Caspase Activation
Treatment with caffeine, an inhibitor of ATR and ATM, or
siRNA targeted to ATR, abrogates Vpr-induced G2 arrest and
apoptosis [14,17,18]. One possible explanation for these
observations would be that Vpr induces apoptosis as a
downstream consequence of sustained G2 checkpoint activa-
tion. This idea, however, is inconsistent with a previously
published model in which Vpr was proposed to directly bind
to the mitochondrial ANT to cause release of proapoptotic
factors in a cell cycle–independent manner [23,24].
To begin to differentiate between these models, we
studied the kinetics of induction of G2 arrest and apoptosis.
If apoptosis were a consequence of G2 checkpoint signaling,
we would predict that G2 arrest should precede the onset of
apoptosis. However, if Vpr were binding ANT to induce
apoptosis, we would predict that commitment to apoptosis
should be independent of cell cycle status and would occur
early following expression of Vpr. We transduced a human
CD4
þ T-lymphocyte cell line, SupT1, with lentiviral vectors
(pHR-VPR-G or pHR-VPR-R) expressing Vpr and either
green ﬂuorescent protein (GFP) or monomeric red ﬂuo-
rescent protein (mRFP), respectively, with an intervening
internal ribosome entry site (Figure 1A). Having essentially
identical vectors with different ﬂuorescent tags allowed us
to stain infected cells with a variety of ﬂuorescent indicators
of cell cycle proﬁle and apoptosis. As a control, we used
isogenic vectors expressing a mutant form of Vpr, pHR-
VPR(R80A), wherein Vpr(R80A) is defective in induction of
G2 arrest and apoptosis [17,25–27]. These vectors were
previously described in detail [13,17,26]. In parallel experi-
ments, we transduced SupT1 cells with VSV-G pseudotyped,
env-defective vector derived from HIV-1NL4–3 (DHIV3;
Figure 1A) or a mutant form of the previous vector with
Vpr deleted (DHIV3-DVPR). At various time points, cultures
were harvested and partitioned for further analyses.
Analyses included cell cycle proﬁle, induction of apoptosis
as measured by caspase activation, and Western blot to
detect release of Smac (second mitochondria-derived acti-
vator of caspase) into the cytoplasm.
Accumulation of Vpr-expressing cells at G2 began at 24 h
post-transduction, peaked at 48 h, and persisted throughout
the remainder of the experiment (Figure 1B). In contrast,
caspase activation in Vpr-expressing cells was ﬁrst detected at
36 h and continued to increase throughout the remainder of
the experiment (Figure 1C). Release of Smac (Figure 1D) also
occurred late, between 72 and 96 h post-transduction.
Samples of ﬂow cytometry charts from experiments shown
in Figure 1C at the 72-h time point are presented in Figure
1E.
Therefore, induction of G2 arrest is an early Vpr-mediated
event, whereas release of Smac and caspase activation lag in
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Synopsis
HIV-1 encodes a small gene known as vpr (viral protein regulatory)
whose product is a 96–amino acid protein. HIV-1 infects cells of the
immune system, such as CD4-positive lymphocytes. When cells
become infected with HIV-1, two deleterious effects result from
expression of the vpr gene. One effect of vpr is to manipulate the
cell cycle by blocking the cells in G2 (the phase of the cell cycle
immediately preceding mitosis). Thus, cells infected with HIV-1 cease
to proliferate, due to the action of vpr. A second effect of vpr is the
induction of cell death by a process known as apoptosis or
programmed cell death. When cells die by apoptosis, they do so
following activation of a cellular set of genes and proteins whose
primary function is to inactivate various cellular functions that are
needed in order to maintain cellular viability. In this study, Andersen
et al. demonstrate that the above two effects of vpr are linked. In
particular, the authors show that the blockade in cell proliferation in
G2 is a requirement toward the onset of programmed cell death.
Programmed cell death can be accomplished by a number of
cellular proteins known as ‘‘executioners.’’ Various executioner
proteins reside on the mitochondrial membranes and may trigger
release of factors from the mitochondria, which in turn will
precipitate the onset of apoptosis. In this work Anderson et al.
identify the mitochondrial protein, Bax, as the key executioner of
apoptosis in the context of HIV-1 vpr. The authors’ findings provide
important mechanistic understanding of how the vpr gene
contributes to HIV-1–induced cell death.Figure 1. Vpr-Induced Caspase Activation and Smac Release from the Mitochondria Are Temporally Delayed in Relation to G2 Arrest
(A) pHR-VPR-G and pHR-VPR-R are bicistronic lentiviral vectors that encode HIV-1NL4–3 vpr, an internal ribosome entry site, and either the gene for GFP
or that for mRFP, respectively; pHR-VPR(R80A) was derived from pHR-VPR (both the mRFP and the GFP versions) by site-directed mutagenesis; DHIV3 is
an envelope-truncated (see gray box) version of HIV-1NL4–3; DHIV3-DVPR was derived from DHIV-3 by introducing a frameshift mutation in vpr.
(B) SupT1 T lymphocytes were transduced by spin-infection in the presence of 10 lg/ml Polybrene with indicated vectors. Mock-infected cells were
subjected to spin-infection in the presence of 10 lg/ml Polybrene without virus. Cells were collected at specified time points post-transduction, stained
with propidium iodide, and analyzed for DNA content by flow cytometry to determine cell cycle profiles. The percentage of cells transduced with pHR
vectors and DHIV3 viruses ranged between 70% to 80% and between 65% to 70%, respectively, as determined by mRFP or GFP expression (with pHR
vectors) or intracellular p24 staining (with DHIV3 vectors).
(C) Caspase activation was measured as an indication of apoptosis. SupT1 cells were infected with indicated vectors, harvested, and incubated with
FITC-VAD-FMK. The percentage of caspase-active cells at each time point was measured by flow cytometry.
(D) Infected SupT1 cells were lysed, and lysates were fractionated into mitochondrial (m) and cytoplasmic (c) fractions and then assayed by Western
blot. Western blots were probed with antibodies specific to Smac to measure release from mitochondria and with anti-VDAC antibodies to measure
mitochondrial contamination in the cytoplasmic fractions. As a positive control for apoptosis, SupT1 cells were treated with 0.8 lg/ml doxorubicin (dox)
for 48 h.
(E) Examples of flow cytometric analysis of caspase activation, corresponding to the 72-h time points from (C).
doi:10.1371/journal.ppat.0020127.g001
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Vpr-Induced Apoptosis, Cell Cycle, and BaxFigure 2. The Apoptotic Effect of Vpr Is Lost in Cells Synchronized in G1/S
(A) HeLa cells were transduced with pHR-VPR-G or mock-transduced and then incubated with 2 mM thymidine. After 24 h of incubation, cells were
harvested,stainedwithPI,andanalyzedforDNAcontentbyflowcytometrytodeterminethepercentageofcellsinG1/SandG2/M.Transductionefficiency
ofpHR-VPRinboththymidine-treatedandcyclingcellswas70%to75%asdeterminedbyanalysisofGFPexpressionbyflowcytometry(unpublisheddata).
(B) Cells from experiments shown in (A) were stained for DAPI at 72 h postinfection, in order to evaluate apoptosis via chromatin morphology
(C) Quantitation of apoptosis in DAPI-stained samples shown in (B); incubation with 25 lM etoposide for 48 h or 1 lM staurosporine for 8 h was
included in both cycling and thymidine-treated cells, for comparative purposes.
(D) Cycling or thymidine-synchronized HeLa cells were mock-transduced or transduced with either pHR-VPR-R or pHR-VPR(R80A) for apoptosis analysis,
using FITC-VAD-FMK. As positive controls for apoptosis, cycling and synchronized cells were treated with etoposide or staurosporine as shown in (C).
(E) Cycling or thymidine-synchronized HeLa cells expressing Vpr or treated with 25 lM etoposide for 48 h were lysed and analyzed by Western blot for
PARP cleavage as a marker of apoptosis/caspase activity. The caspase-cleaved PARP band is observed at 89 kDa.
(F) Cell lysates from pHR-VPR–transduced cells, with or without thymidine block, were harvested at 12 and 24 h post-transduction and analyzed by
Western blot for Vpr expression with antibodies specific to the amino-terminal hemagglutinin tag.
doi:10.1371/journal.ppat.0020127.g002
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Vpr-Induced Apoptosis, Cell Cycle, and Baxrelation to cell cycle arrest by approximately 24 h. Since G2
arrest clearly precedes apoptosis, we found it compelling to
ask whether transition into G2 was required for the commit-
ment to apoptosis in Vpr-expressing cells.
G1/S Block Abolishes the Induction of Apoptosis by Vpr
We designed an experiment to prevent Vpr-expressing
cells from entering G2 and then asked whether these cells
would still be susceptible to Vpr-induced apoptosis. We
chose to perform the experiment in HeLa cells since these
cells can be synchronized by incubation with 2 mM
thymidine with minimal toxicity [28]. HeLa cells represent
an appropriate cell type to study Vpr-induced apoptosis,
because ATR activation, breast cancer–associated protein 1
(BRCA1) phosphorylation, and GADD45a upregulation are
conserved from HeLa cells to primary human CD4
þ
lymphocytes [14,17,26,29]. HeLa cells were transduced with
pHR-VPR-G and, 4 h later, treated with 2 mM thymidine,
which arrests cells at the G1/S boundary [28]. DNA content
analysis showed that thymidine treatment effectively
synchronized uninfected cells in G1/S (Figure 2A). Thymidine
synchronization of pHR-VPR-G–infected cells resulted in
82.9% cells in G1/S and 17.0% cells in G2/M. The
comparatively high number of cells in G2/M in the
synchronized, pHR-VPR–infected culture (17%) reﬂects cells
that reached G2/M prior to synchronization and arrested due
to Vpr expression. To evaluate the frequency of apoptotic
cells in these cultures, cells were stained with the nuclear dye
49,6-diamidino-2-phenylindole dihydrochloride (DAPI). DA-
PI binds to chromatin and reveals the presence of a
conspicuous pyknotic nuclear morphology that is associated
with late stages of apoptosis. We have previously described
the use of DAPI for analysis of Vpr-induced apoptosis
[17,30]. Figure 2B shows ﬂuorescence microscopy photo-
graphs from this analysis, and quantitations are shown in
Figure 2C. DAPI staining revealed that at 48 h post-
transduction, 23% of cells transduced with Vpr were
apoptotic if allowed to cycle, whereas only 7% were
apoptotic if treated with thymidine (Figure 2C). The back-
ground level of apoptosis in uninfected cells treated with
thymidine was 4%.
To address whether the decreased sensitivity of G1/S-
arrested cells to Vpr-induced apoptosis could be due to
thymidine treatment itself, cells were treated with a pharma-
cologic apoptosis inducer (etoposide or staurosporine) and
then allowed to cycle, or not (thymidine incubation).
Staurosporine is a kinase inhibitor and potent inducer of
apoptosis with no known cell cycle speciﬁcity. Etoposide is a
topoisomerase II inhibitor and an inducer of double-strand
breaks (DSBs) and, like Vpr, causes G2 arrest [31,32]. Treat-
ment with staurosporine or etoposide effectively induced
apoptosis in both G1/S-arrested and cycling cells (Figure 2C).
To conﬁrm the previous apoptosis results, we performed
parallel experiments using pHR-VPR-R and staining for
caspase activity with FITC-VAD-FMK (Figure 2D) and by
measuring poly-ADP-ribose polymerase (PARP) cleavage
(Figure 2E). Analysis of Vpr expression by Western blot
revealed that thymidine treatment did not affect expression
of Vpr (Figure 2F). These results are in agreement with those
obtained by DAPI staining and conﬁrm that synchronization
of cells in G1/S alleviates Vpr-induced apoptosis.
Release of Vpr-Expressing Cells from G1/S Block Leads to
G2 Arrest-Dependent Apoptosis
The previous results indicate that the proapoptotic effect
of Vpr is lost when cells are artiﬁcially maintained in G1/S. To
determine whether induction of apoptosis by Vpr speciﬁcally
requires transition into G2, cells were synchronized as in the
previous experiment and then were released from thymidine
block and allowed to reenter the cell cycle. Released cells
were harvested at speciﬁed intervals to examine cell cycle
progression (Figure 3A) and apoptosis (Figure 3B). Both
mock-treated and Vpr-expressing cells entered G2 at 12 h
postrelease. Mock-infected cells completed the ﬁrst division
cycle at 18 h postrelease and continued to cycle (Figure 3A,
upper panels), while cells expressing Vpr persisted in G2 for
the remainder of the experiment (Figure 3A, lower panels). A
small amount of cells (17.4%) in the Vpr-transduced culture
reached G1 at 18 h postrelease. The reason for this is that the
efﬁciency of transduction with pHR-VPR was about 80% and
therefore about 20% are untransduced.
We then asked when, after release from the thymidine
block, Vpr-expressing cells would enter apoptosis. Cells which
were synchronized, maintained in G1 for 48 h, and then
released (Figure 3B, lanes 2–6) began to display detectable
PARP cleavage by 12 h postrelease (Figure 3B, lane 3).
Therefore, the onset of apoptosis in Vpr-expressing cells is
concomitant with entry into the G2 phase. In the absence of
synchronization in G1 (Figure 3B, lanes 7–11), Vpr-expressing
cells begin to display PARP cleavage by 24 h post-trans-
duction. Synchronized cells, in the absence of Vpr expression,
did not display PARP cleavage after release (unpublished
data).
Parallel samples from the previous synchronization experi-
ment were also analyzed by DAPI staining (Figure 3C). These
experiments revealed chromatin fragmentation/condensation
in Vpr-expressing cells at 24 and 48 h postrelease (Figure 3C).
Taken together, these data indicate that Vpr-induced
apoptosis requires entry into the G2 phase and artiﬁcially
maintaining cells in G1 effectively prevents the onset of
apoptosis.
Inhibition of ATR Prevents Vpr-Induced Apoptosis but
Exacerbates Genotoxin-Induced Apoptosis
Due to the phenotypic similarities between Vpr and
genotoxic stress, many studies on Vpr have been modeled
based on the current understanding of DNA damage signal-
ing [12,14,33]. Several reports have shown that suppression of
G2 checkpoint-activating kinases after exposure to genotoxic
agents overrides cell cycle arrest but exacerbates apoptosis
[34–37]. The reason for this increase in cell death is thought
to be the inability of cells to successfully duplicate DNA or to
align and segregate damaged chromosomes during mitosis
(reviewed in [35]). Thus, we set out to compare in parallel the
effect of ATR suppression on Vpr- versus genotoxin-induced
apoptosis. We reasoned that if Vpr causes irreparable DNA
damage, then the effect of checkpoint overriding on Vpr-
induced apoptosis should mirror that of cells treated with
genotoxic agents. To test this, we treated cells with siRNAs
speciﬁc to ATR, ATM, or nonspeciﬁc siRNA. At 48 h
following siRNA transfection, we treated cells with 25 lM
N-methyl-N9-nitro-N-nitrosoguanidine (MNNG), an SN1-type
methylating agent and inducer of G2 arrest, or 25 lM
etoposide. At 24- and 48-h time points following the addition
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Vpr-Induced Apoptosis, Cell Cycle, and BaxFigure 3. Release of Vpr-Expressing Cells from Thymidine Block Leads to Reentry into the Cell Cycle and Vpr-Induced, G2-Dependent Apoptosis
(A) Thymidine-synchronized HeLa cells transduced with pHR-VPR-G or mock-transduced were released from thymidine block and harvested at specified
time points postrelease. Cells from each time point were stained with PI and analyzed for DNA content by flow cytometry.
(B) pHR-VPR–transduced HeLa cells from the same experiment were monitored by Western blot for PARP cleavage at specified time points. Time points
labeled under ‘‘Thym þ pHR-VPR’’ indicate hours following release from thymidine block; time points under ‘‘pHR-VPR’’ indicate hours following
transduction, as these cells were not synchronized.
(C) Cells treated as those in (A) and (B) were harvested at 24 and 48 h were analyzed for apoptosis by DAPI staining, and the results are quantified.
doi:10.1371/journal.ppat.0020127.g003
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Vpr-Induced Apoptosis, Cell Cycle, and Baxof etoposide or MNNG, we measured caspase activation
(Figure 4A and 4B; for simplicity, only one time point is
shown in 4A). Knockdown of ATR dramatically exacerbated
etoposide- and MNNG-induced apoptosis (14.5% to 60.7%
and 6.2% to 35.4%, respectively, at 48 h). Knockdown of ATM
led to a modest increase in genotoxin-induced apoptosis
(14.5% to 21.3% for etoposide and 6.2% to 10% for MNNG,
at 48 h). In contrast, Vpr-induced caspase activation was
dramatically inhibited by ATR knockdown (from 41.2% to
14.2%) but was unaffected by ATM knockdown (41.2% to
39.4%). DAPI staining showed a similar ATR-dependent
decrease in Vpr-induced apoptosis (Figure 4C). The level of
knockdown achieved by each siRNA was determined by
Western blot with antibodies speciﬁc for the endogenous
proteins (Figure 4D).
In conclusion, we demonstrated the requirement for ATR
checkpoint activation through two different methodologies:
(a) manipulation by G1/S synchronization and (b) ATR
knockdown. We also conclude that this aspect of Vpr
function represents a departure from the manner in which
checkpoint activation relates to apoptosis in the context of
genotoxic agents.
Vpr-Induced Apoptosis Does Not Require ANT but Is
Mediated via Bax, Downstream of ATR Activation
Early reports suggested that the permeability transition
pore complex (PTPC), which consists of VDAC, ANT, and
cyclophilin D, was involved in release of apoptotic factors
from the mitochondria in response to various apoptotic
stimuli (reviewed in [38]) and, in particular, for Vpr [23].
However, later reports have put in question the role of the
PTPC in DNA damage–induced apoptosis [39–42]. For
example, mouse cells deﬁcient in ANT are fully capable of
undergoing apoptosis in response to DNA damage and,
instead, show increased resistance to necrosis in response to
high intracellular Ca
2þ [39]. Mouse cells deﬁcient in cyclo-
philin D, which is required for VDAC function, are fully
capable of undergoing apoptosis in response to genotoxins
[40,42]. Large oligomeric complexes containing Bax and
possessing apoptotic pore function do not contain ANT or
VDAC [43]. Bax is required for activation of the mitochon-
drial pore-forming complex that responds to DNA damage
(reviewed in [44,45]) and the pore-forming function of Bax is
independent of ANT or VDAC [43,46–48].
Thus, we asked whether Vpr-induced apoptosis is mediated
through ANT or, alternatively, through Bax. We addressed
this question using siRNAs that would speciﬁcally down-
regulate Bax or ANT, in the context of pHR-VPR-R trans-
duction. Bax knockdown led to a dramatic decrease in Vpr-
induced apoptosis (from 41.2% in the presence of nonspeciﬁc
siRNA to 12.6% in the presence of Bax siRNA; Figure 4A),
whereas ANT knockdown had no appreciable effect on
apoptosis (41.2% versus 39.5%; Figure 4A). These results
were also conﬁrmed by analysis of DAPI-stained nuclei
(Figure 4C). The levels of knockdown achieved by each siRNA
are shown in Figure 4D.
Activation of Bax is associated with a conformational
change that exposes an N- terminal epitope detected by
monoclonal antibody Bax6A7 [49]. Thus, reactivity with
Bax6A7 provides a direct measurement of Bax activation.
To probe for Bax activation in the presence of Vpr,
peripheral blood CD4
þlymphocytes were infected with either
DHIV3 or DHIV3-DVPR, cells were lysed, and immunoreac-
tivity with Bax6A7 antibody was tested by immunoprecipita-
tion followed by Western blot (Figure 4E). Reactivity with
Bax6A7 was increased following infection with DHIV3, when
compared with that of mock- or DHIV3-DVPR–infected cells.
Our previous studies established that Vpr-induced ATR
activation leads to BRCA1 phosphorylation and GADD45a
upregulation and that both ATR and GADD45a are required
for Vpr-induced apoptosis [14,17]. Based on previous ﬁndings
and data reported here, we propose that ATR activation is an
upstream signaling event in the pathway leading to Vpr-
induced cell cycle arrest and apoptosis. If this were correct,
then it would follow that Bax activation by Vpr is also ATR
dependent. In order to examine the requirement of ATR in
Vpr-induced Bax activation, we treated cells with siRNAs
speciﬁc to either ATR or GADD45a prior to transduction
with pHR-VPR-R. We observed that the increase in Bax6A7
reactivity was reduced to basal levels in the presence of either
ATR or GADD45a knockdown but not when using a
nonspeciﬁc siRNA (Figure 4F). Therefore, these results
provide additional support for a model in which Bax
activation is a principal effector of Vpr-induced apoptosis
downstream of G2 checkpoint activation by the ATR kinase.
Effect of Vpr on Mitotic Entry
It is unclear whether cells arrested in G2 by Vpr transition
into mitosis. Early measurements of the mitotic index
suggested that Vpr induced G2 arrest and concomitantly
inhibited entry into mitosis [50–53]. Later studies, however,
showed that cells expressing Vpr develop mitotic abnormal-
ities such as multipolar spindles, mislocalization of certain
spindle pole body proteins, and defects in cytokinesis [54,55],
collectively indicating mitotic entry. To reexamine the issue
of mitotic entry in the context of Vpr, we measured
phosphorylation of histone 3 (H3) at serine-10 [56,57] in the
presence of Vpr (Figure 5). As positive and negative controls,
we incubated cells with nocodazole (lanes 2 and 6) and
doxorubicin (lanes 3 and 7), respectively. Doxorubicin is a
genotoxic agent that intercalates into DNA, inhibits top-
oisomerase 2 and induces G2 arrest via Cdc2 Tyr15
phosphorylation, without allowing mitotic entry. Nocodazole
arrests cells in mitosis and exerts its effect by depolymerizing
microtubules. HeLa cells transduced with pHR-VPR dis-
played a high level of H3 phosphorylation (lane 4), whereas
transduced SupT1 cells displayed no detectable H3 phos-
phorylation (lane 8). Therefore, Vpr expression leads to
mitotic entry in HeLa cells following G2 arrest, whereas Vpr
causes sustained G2 arrest in SupT1 cells without subsequent
mitotic entry.
Analysis of G2 Arrest and Apoptosis Induction by Clinically
Relevant Vpr Alleles and by a Vpr-GFP Fusion Chimera
Several natural or laboratory-constructed mutants of HIV-
1 Vpr have been reported that selectively ablate either G2
arrest or apoptosis. These mutants can be categorized into
two groups. The ﬁrst group includes vpr alleles with amino
acid substitutions that have been observed in long-term
nonprogressors, with a reduced ability to cause apoptosis but
with normal induction of G2 arrest. These substitutions
include Q3R [22], R77Q [21], and I47A [58]. The second group
includes Vpr-GFP and GFP-Vpr fusion proteins. In partic-
ular, it was reported that while a GFP-Vpr (whereby Vpr is
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(A) HeLa cells were transfected with nonspecific (NS) siRNA or siRNA targeted to ATR, or ATM as indicated. At 48 h post-transfection, cells were either
treated with 25 lM etoposide, treated with 25 lM MNNG, mock-transduced, or transduced with pHR-VPR-R. Additionally, cells transfected with siRNAs
targeted to Bax or ANT were transduced with pHR-VPR-R or mock-transduced (lower left dot plots). Cells from each treatment were assayed for caspase
activity as in Figure 2B.
(B) Cells treated as in (A) were harvested at specified time points post-transduction and assayed for caspase activity.
(C) Cells treated as in (A) were stained with DAPI, and the results were quantified by microscopy.
(D) Cells treated with the indicated siRNAs were lysed and analyzed by Western blot to verify knockdown efficiency.
(E) Primary human CD4
þ lymphocytes were infected with DHIV3, infected with DHIV3DVPR, or mock-infected. At 48 h postinfection, cells in each
treatment were lysed and assayed for protein concentration. Equal amounts of protein from each treatment were incubated with Bax6A7 monoclonal
antibody. Antibody–protein complexes were precipitated with agarose beads and boiled and then subjected to Western blot analysis with a polyclonal
antibody to Bax.
(F) HeLa cells treated with the indicated siRNAs and transduced with pHR-VPR or mock-transduced were lysed; reactivity to Bax6A7 antibody was
assayed as described in (E).
doi:10.1371/journal.ppat.0020127.g004
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G2 arrest and apoptosis induction, the reciprocal chimera,
Vpr-GFP, was able to induce apoptosis in the absence of G2
arrest [59]. Collectively, the data obtained with both groups of
mutants would appear to support that induction of G2 arrest
and apoptosis are independent, separable functions of Vpr.
We wished to examine the phenotype of these mutants and
chimeras using the experimental paradigms we described in
Figure 1.
The Vpr mutants, R77Q and I74A, were separately
constructed in the background of pHR-VPR-R (which
encodes HIV-1NL4–3 vpr). Lentiviral vectors were then
produced and used to infect target cells. Transduced cells
were then evaluated for cell cycle stage at 48 h and for
apoptosis at 72 h (Figure 6A). The levels of apoptosis, as
judged by staining with FITC-VAD-FMK, were very similar
between wild-type Vpr, Vpr(R77Q), and Vpr(I74A) and the
levels of G2 arrest were also similar. To more directly assess
whether the frequencies of G2 arrest and apoptosis correlated
with each other, we calculated the ratio of cells in apoptosis
over cells in G2 for each mutant Vpr (% apoptotic cells/%
cells in G2/M [Apo/G2M]). If a Vpr mutant induces normal
levels of G2 arrest, but reduced levels of apoptosis, then the
Apo/G2M ratio should decrease. The Apo/G2M ratios were
0.83 for wild-type Vpr, 0.91 for Vpr(R77Q), and 0.92 for
Vpr(I74A). Therefore, we conclude that neither of the Vpr
mutants tested here resulted in lower levels of apoptosis
induction, when compared to wild-type Vpr.
We previously demonstrated that Vpr induced phosphor-
ylation BRCA1 at residue Ser1423 by the ATR kinase and that
this phosphorylation correlated with induction of apoptosis
[17]. To examine whether the Vpr mutants had a normal
ability to induce BRCA1 phosphorylation, we performed
Western blot on lysates from cells infected with the above
lentiviral vectors. Wild-type Vpr and mutants were able to
induce BRCA1 phosphorylation, and this phosphorylation
was, in all three cases, ablated by treatment with caffeine
(Figure 6B). Therefore, we were unable to ﬁnd any detectable
differences in the functions of Vpr(R77Q) or Vpr(I74A) when
compared with Vpr(R77).
We then examined the phenotype of a Vpr-GFP fusion
protein. It is well known that the addition of recombinant
amino acid sequences as small as the inﬂuenza hemagglutinin
tag at the carboxyl terminus of Vpr results in failure of Vpr to
activate the G2 checkpoint [25]. Carboxyl-terminal addition
of larger fusion partners, such as luciferase [25] or GFP [59],
also results in ablation of the G2 arrest. Waldhuber et al. [59]
found that carboxyl-terminal addition of GFP resulted in a
Vpr chimera that was fully able to induce apoptosis. We
constructed a Vpr-GFP chimera and observed that it was, as
expected, unable to induce G2 arrest (unpublished data). We
then examined the induction of apoptosis by the fusion
protein. To generate an appropriate control, we introduced
the R80A mutation in the fusion construct, to generate
Vpr(R80A)-GFP, and tested its ability to induce apoptosis
(Figure 6C). Both Vpr-GFP and Vpr(R80A)-GFP were able to
induce apoptosis. Since Vpr(R80A) that is not fused to GFP is
unable to induce apoptosis (Figures 1 and 2), we expected
that the introduction of the R80A substitution in the Vpr-
GFP fusion protein [Vpr(R80A)-GFP] would also result in a
protein devoid of apoptosis induction. Surprisingly,
Vpr(R80A)-GFP is also capable of inducing apoptosis.
Because the fusion with carboxyl-terminal GFP turns
Vpr(R80A), a nonproaptotic protein, into an apoptotic one,
it appears that the induction of apoptosis by Vpr-GFP
represents a gain-of-function phenotype and is not repre-
sentative of the biology of wild-type Vpr.
In conclusion, our results suggest that induction of G2
arrest and apoptosis by HIV-1 Vpr are functionally interre-
lated and not genetically separable.
Discussion
The Functional Relationship between G2 Arrest and
Apoptosis
One gap in our current understanding of checkpoint
signaling and apoptosis lies between the activation of nuclear
checkpoint sentinels, such as ATR and ATM, and the
involvement of Bcl-2 family of apoptosis regulators at the
mitochondria. Previous reports have suggested that nuclear
proteins, such as Rad9 or Histone H1, may translocate from
the nucleus to the cytoplasm in response to DNA damage, to
interact with mitochondrion-associated Bcl-2 family proteins
and promote cytochrome c release and apoptosis [60,61]. In
other instances of DNA damage, activated p53 was shown to
directly promote Bax activation [62,63]. However, loss of p53
does not abrogate induction of apoptosis by Vpr [30,64], and
we have been unable to observe Rad9 or histone H1
translocation to the mitochondria in response to Vpr (J. L.
Andersen and V. Planelles, unpublished data). These obser-
vations, taken together with the results presented here,
indicate that Vpr links checkpoint activation and apoptosis
Figure 5. Vpr Induces Histone 3 Phosphorylation in HeLa but Not in
SupT1 Cells
HeLa or Supt1 cells were transduced with pHR-VPR-G and at indicated
time points, lysed, and analyzed by Western blot with a phospho-specific
antibody that recognizes phosphorylation of H3 at serine-10. Nocodazole
(250 ng/ml) and doxorubicin (1 lM) were used as positive and negative
controls, respectively.
doi:10.1371/journal.ppat.0020127.g005
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for entry into G2 (Figure 7A).
In support of a cause–effect relationship between Vpr-
induced G2 arrest and apoptosis, several reports demonstrate
that the apoptotic effect of Vpr can be overridden by
suppressing G2-speciﬁc cell cycle–regulating kinases [17–20].
Yuan et al. [19,20] found that Wee1, a kinase which negatively
regulates Cdk1 activity and thus regulates the G2-to-M
transition, is activated by Vpr. Furthermore, Yuan et al.
[19,20] showed that suppression of Wee1 in the presence of
Vpr abrogated both Vpr-induced G2 arrest and apoptosis.
The Role of ATR in Vpr-Induced Apoptosis Differs from Its
Role in Genotoxic Stress-Induced Apoptosis
We also demonstrate that ATR knockdown exacerbates
genotoxin-induced apoptosis but, surprisingly, relieves Vpr-
induced apoptosis [17]. The different effects of ATR knock-
down on Vpr- versus genotoxin-induced apoptosis suggest
that Vpr activity fundamentally differs from genotoxic stress.
More speciﬁcally, it is tempting to speculate that such a
difference resides in the fact that Vpr does not cause physical
DNA damage (such as DSBs) whereas genotoxic agents do. In
fact, three lines of evidence indicate that Vpr activates ATR
in a manner that does not involve generation of DSBs: (1)
Pulse-ﬁeld gel electrophoresis revealed no DSBs in vpr-
expressing cells [12]. (2) Vpr fails to induce phosphorylation
of ATM at serine-1981, a residue linked to DSB signaling and
potently phosphorylated in response to ionizing radiation
[12]. (3) And, as we have shown here, in contrast with
etoposide-induced apoptosis, Vpr-induced apoptosis is re-
lieved under conditions of checkpoint suppression.
Models for Vpr activity that would be in agreement with
Figure 6. Functional Analysis of Vpr Mutants
(A) SupT1 cells were infected with pHR-VPR-R or indicated mutants, at an MOI of 0.5. At 48 h postinfection, cells were stained with hypotonic PI to
determine the cell cycle profiles. At 72 h postinfection, cells were incubated with FITC-VAD-FMK and analyzed by flow cytometry to determine the
percentage of cells with active caspases.
(B) Cells from above treatments were lysed at 48 h postinfection, and Western blot was performed to assay for phosphorylation of BRCA1 at Ser1423 by
the ATR kinase. To establish the role of ATR in BRCA1 phosphorylation, parallel infections were treated with caffeine (2 mM).
(C) Induction of apoptosis by Vpr-GFP and Vpr(R80A)-GFP fusion proteins. HPB-ALL cells were transfected with indicated constructs or mock-transfected
and 48 after transfection, phosphatidylserine exposure was analyzed by flow cytometry using phycoerythrin-conjugated annexin V.
doi:10.1371/journal.ppat.0020127.g006
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past. For example, Vpr may perturb nuclear envelope
integrity, as suggested by de Noronha et al. [65]. Perturbation
of nuclear envelope integrity may, in turn, lead to ATR
activation. In addition, Lai et al. proposed that Vpr binds
directly to chromatin in a manner that results in ATR
activation [12].
Role of the Mitochondria in Vpr-Induced Apoptosis
Previous reports have suggested that Vpr induces apoptosis
via a direct interaction with ANT at the inner mitochondrial
membrane, which results in release of cytochrome c from
fractionated mitochondria [23]. These observations would
indicate that Vpr induces mitochondrial depolarization
directly, rather than activating upstream stress signals, and
suggest that Vpr may induce apoptosis rapidly after being
expressed (Figure 7B). We reasoned that if Vpr induced
apoptosis by interacting directly with the mitochondria, it
would efﬁciently induce apoptosis regardless of cell cycle
status. In contrast with the previous expectation, we observed
that cell cycle transition into G2 is required for Vpr to induce
apoptosis. Furthermore, blockade of the cell cycle in G1 for
48 h effectively prevented apoptosis, and subsequent release
of the block allowed apoptosis induction, coinciding with
entry into G2.
Jacotot et al. [23] proposed that the mitochondrial channel
activated by Vpr is the PTPC. In sharp contrast, we ﬁnd that
efﬁcient removal of ANT (an essential domain of PTPC) did
not affect Vpr apoptosis to any degree. Instead, removal of
Bax, an independent mitochondrial pore-forming protein,
led to nearly complete suppression of apoptosis. Further-
more, Bax activation is dependent on the presence of ATR, as
is induction of apoptosis. Taken together, our data strongly
support a model in which the apical step toward Vpr-induced
apoptosis is activation of ATR, followed by the activation of
downstream apoptotic mediators such as Bax, Smac, and
caspases (Figure 7).
Role of Vpr in HIV-1 Pathogenesis
Depletion of CD4
þ lymphocytes due to HIV-1 infection
leads to immune suppression in AIDS patients (reviewed in
[66]). The cause of T-cell depletion in AIDS patients is a
question under intense research but remains poorly under-
stood. The discovery of mutations in Vpr that may be
associated with long-term nonprogressors and impair the
apoptosis-inducing ability of Vpr suggests a critical role for
Vpr in AIDS pathology [21,22,58]. However, for the Vpr
mutation, R77Q, a recent report has questioned its association
with long-term nonprogressors [67]. Fisher et al. [67] proposed
that R77Q is associated with certain viral subtypes, such as
subtype A, and not with disease progression. A more recent
analysis of the GenBank database revealed that R77 predom-
inates in subtype B, whereas Q77 predominates in clades A, C,
D, G, and H and groups O and N viruses, and subtype F and K
strains frequently encode H77 [68]. Rajan et al. [68] also
reported, using isogenic, full-length viruses, that HIV-1
carrying Q77 displayed reduced cytopathicity if the virus
had R5 tropism but not if it had X4 tropism. The previous
experiments did not uncouple the cytopathic potential of the
virus strains from their replication kinetics. Therefore, in our
studies, we wished to examine the proapoptotic potential of
mutant Vpr proteins in the context of a nonreplicating
lentiviral vector and in the absence of other viral genes. Our
results conclusively show that in our experimental paradigm,
the proapoptotic potentials of Vpr(R77Q) and Vpr(I74A) are
indistinguishable from that of Vpr(R77). Thus, the results by
Rajan et al. [68] would seem to indicate that the R77Q
substitution has a moderate, positive effect on cell viability,
and this effect may be related to viral replication efﬁciency
rather than to proapoptotic signaling.
Materials and Methods
Western blotting procedures. For PARP and HA-Vpr detection,
cells were detached with trypsin, washed once with media containing
10% fetal bovine serum, and then washed twice in PBS. Detached
cells were pelleted by centrifugation and then resuspended in ice-
cold lysis buffer (20 mM Tris [pH 7.5], 100 mM NaCl, 0.5% NP-40, 0.5
mM EDTA) in the presence of Complete Protease Inhibitors (Roche,
http://www.roche.com). Cell lysates were passed through a 25-gauge
needle ten times and then resuspended in Criterion loading buffer
(Bio-Rad, http://www.bio-rad.com). Next, 20 lg of cell lysate per
sample was loaded on a Criterion XT 10% polyacrylamide gel (Bio-
Rad). Following electrophoresis (at 50 amps/gel), proteins were
transferred to Immobilon FL PVDF membranes (Millipore, http://
www.millipore.com) and then immunostained with anti-PARP (Cell
Signaling Technologies, http://www.cellsignal.com) and anti-rabbit
680 (Invitrogen, http://www.invitrogen.com) antibodies. The primary
anti-PARP antibody was diluted 1:1,000 in TPBS (PBS, 0.1% Triton-X
100) plus 5% nonfat dry milk (NFDM). The secondary anti-rabbit 680
antibody was diluted 1:10,000 in TPBS plus 5% NFDM and 0.1%
sodium dodecyl sulfate (SDS). Blots were incubated with secondary
antibody for 1 h at 4 8C and then washed 5 times with TPBS. Protein
bands were visualized by the Odyssey infrared system (LI-COR
Biosciences, http://www.licor.com). Protein concentrations of all
samples were determined by BCA protein assay (Pierce Biotechnol-
ogy, http://www.piercenet.com) prior to loading.
For all other Western blots, the above protocol was followed with
Figure 7. Models to Explain the Activities of HIV-1 Vpr
(A). Activation of ATR by Vpr and downstream signaling consequences
leading to both G2 arrest and apoptosis. The functional link between
GADD45a and activation of Bax and the mechanism by which G2 arrest
leads to Bax activation remain unknown (question marks).
(B) Binding of Vpr to mitochondrial PTPC was proposed to trigger release
of cytochrome c and induction of apoptosis, independently of cell cycle
status; in this work, we propose that an alternative pore-forming
mitochondrial protein, Bax, is the effector of Vpr-induced apoptosis, and
that Bax activation requires upstream stress signals derived from ATR.
doi:10.1371/journal.ppat.0020127.g007
PLoS Pathogens | www.plospathogens.org December 2006 | Volume 2 | Issue 12 | e127 1116
Vpr-Induced Apoptosis, Cell Cycle, and Baxthe exception that secondary HRP-conjugated antibodies were
diluted in TPBS plus 5% NFDM and bands were visualized by ECL
detection, using ECL plus (Amersham Biosciences, http://www.
amersham.com). For Bax 6A7 immunoprecipitation, cells were lysed
in CHAPS buffer (10 mM HEPES, 150 mM NaCl, 1% CHAPS,
protease inhibitors) on ice for 10 min, followed by ten passes through
a 25-gauge needle. Then, 2 lg of Bax 6A7 monoclonal antibody
(Abcam, http://www.abcam.com) was added to 1 mg of cellular protein
and incubated 8 h at 4 8C under constant mixing followed by
incubation with protein A/G beads (Santa Cruz Biotechnology, http://
www.scbt.com) according to the manufacturer’s protocol. Protein–
bead complexes were then washed with lysis buffer 3 times, boiled for
3 min, and subject to Western blot with anti-Bax antibody (Cell
Signaling Technologies) and ECL detection according to methods
described above. Antibodies used were anti-ATR (obtained from Dr.
Paul Nghiem, Harvard University, Boston, Massachusetts, United
States), anti-GADD45 (Santa Cruz Biotechnology), anti-Bax (Cell
Signaling Technologies), anti–cytochrome c (Santa Cruz Biotechnol-
ogy), anti-Smac/Diablo (Imgenex Corporation, http://www.imgenex.-
com), and Bax 6A7 (Abcam).
Cell cycle analysis. Cells were harvested and counted; 1 3 10
6 cells
were aliquoted into tubes and washed once with cold PBS. Washed
cells were resuspended in 0.5 ml of cold PBS, following which 2 ml of
ice-cold ethanol was slowly added with gently vortexing. Ethanol-
ﬁxed cells were left overnight at 20 8C. The following day, cells were
centrifuged at 828 3 g, and ethanol was washed from the cells. Cells
were then resuspended in propidium iodide staining buffer (10 lg/ml
propidium iodide, 2% FBS, 11.25 kU RNase A/ml, 0.02% sodium
azide) and allowed to incubate for 10 min on ice prior to analysis of
DNA content by ﬂow cytometry. Cell cycle proﬁles were further
analyzed using Modﬁt software (Verity Software, http://www.vsh.com)
to derive percentages of cells in different phases of cell cycle.
Viral vectors and virus. DHIV3 and pHR lentiviral vectors were
produced by transient transfection of HEK293T cells. For produc-
tion of pHR vectors, pHR-VPR or pHR-VPR(R80A) was cotrans-
fected with pCMVDR8.2DVPR [69], and pHCMV-VSVG [70] by
calcium phosphate–mediated transfection [18]. Virus-containing
supernatants were harvested at 24, 48, and 72 h post-transfection.
Supernatants were cleared of cellular debris by centrifugation at
828 3 g for 10 min, and virus in cleared supernatants was
concentrated by centrifugation at 115,889 3 g for 2 h at 4 8C.
Virus was titered by infection of HeLa cells and subsequent ﬂow
cytometric analysis of the reporter molecule GFP. Vector titers were
calculated with the equation [(F 3 C0)/V] 3 D, where F is the
frequency of GFP-positive cells found by ﬂow cytometry, C0 is the
total number of target cells at the time of infection, V is the volume
of inoculum, and D is the virus dilution factor. The virus dilution
factor used for titrations was 10. The total number of target cells at
the time of infection for titer was 0.5 3 10
6. Infections were
performed at a multiplicity of infection (MOI) of 2.5 with 10 lgo f
Polybrene/ml for 8 h. Infections of siRNA-treated cells were
performed 48 h after siRNA transfection. T cells and HeLa cells
were transduced with virus diluted in cell culture media with 8 lg/
ml and 10 lg/ml Polybrene, respectively. For HeLa cell transduction,
virus-containing media was washed after 8 h and replaced with fresh
culture media. T cells were transduced by spinoculation as
previously described [71].
The HIV-1 molecular clone HIV-1NL4–3 was transfected into 2 3
10
7 HEK293FT cells by calcium phosphate transfection. At 48 h after
transfection, HEK293FT cells were co-cultured with 10
7 MT-2 cells
for 5 h. MT-2 cells were then cultured alone until approximately 75%
of cell clumps showed syncitia. Virus-containing supernatants were
then cleared of cells and debris by centrifugation at 2,000 rpm for 10
min. Viral stocks were then frozen at  80 8C. Spin infections were
performed as described above.
Apoptosis assays. For analysis of apoptotic nuclear morphology,
cells were ﬁxed in the well with 2% paraformaldehyde (in PBS) for 15
min at room temperature (RT). Fixed cells were then permeabilized
in 0.1% Triton X-100 (in PBS) for 15 min at RT, gently washed 2 times
in PBS, and then incubated in 0.5 lg/ml DAPI (Invitrogen) for 45 min
at 37 8C. Apoptotic nuclei were identiﬁed by ﬂuorescence micro-
scopy, counted, and divided by total cells in the ﬁeld to determine
percent apoptosis. For cell counting, ﬁelds were chosen at random,
and a minimum of 1,000 cells were counted per treatment in each
experiment. Standard deviations were derived from three separate
experiments. PARP cleavage was assayed by Western blot as described
above. For analysis of caspase activity, cells were stained with FITC-
VAD-FMK (Promega, http://www.promega.com) or RED-VAD-FMK
(Calbiochem/EMD Biosciences, http://www.emdbiosciences.com) ac-
cording to manufacturer’s protocols. Caspase-stained cells were
analyzed by ﬂow cytometry.
Phosphatidylserine exposure at the cell surface was analyzed as
previously described [72] by ﬂow cytometry using phycoerythrin-
conjugated annexin V (Annexin V-PE, Bender MedSystems, http://
www.bendermedsystems.com).
siRNA treatments. All siRNA treatments were performed with
Dharmacon anti-human smart pool siRNA duplexes (Dharmacon,
http://www.dharmacon.com). Smart pool siRNAs were transfected at a
ﬁnal concentration of 100 nM into exponentially growing HeLa cells
with Oligofectamine (Invitrogen) according to the manufacturer’s
protocol. Cells were split 1:3 at 24 h post-transfection. At 48 h post-
transfection, cells were harvested to verify knockdown by Western
blot or subject to experimental treatments.
Cell culture. For experiments in which cell synchronization or the
use of siRNAs was to be employed, we used the human cervical cancer
cell line HeLa, which was maintained in Dulbecco’s modiﬁed Eagle’s
medium (Cambrex BioScience (formerly BioWhittaker), http://
www.cambrex.com), supplemented with 10% FCS and 2 mM L-
glutamine. For experiments in which viral transduction and measure-
ment of cell cycle/apoptosis were the aims, we used the human T-cell
line SupT1, which was maintained in RPMI 1640 (Cambrex
BioScience), supplemented with 10% FCS and L-glutamine.
Peripheral blood mononuclear cells were obtained with Leukopaks
from unidentiﬁed, healthy donors (American Red Cross, http://
www.redcross.org), and CD4
þ lymphocytes were puriﬁed using anti-
CD4 magnetic beads (Dynal/Invitrogen) according to the manufac-
turer’s instructions. CD4
þ T cells were activated by culture in RPMI
plus 10% FBS plus 1 mM L-glutamine with 3 anti-CD3/anti-CD28
beads per cell (Invitrogen) for 2 d, changing medium daily. After 2 d,
recombinant interleukin 2 was added to the culture medium at a
concentration of 100 units/ml.
Drug treatments. Thymidine was diluted to a concentration of 2
mM in culture media and then added to exponentially growing HeLa
cells. For experiments in which thymidine treatment was combined
with viral gene expression, thymidine-containing media was added
immediately following transduction. For experiments in which
thymidine treatment was combined with genotoxic drugs, cells were
incubated in thymidine-containing media for 4 h prior to the
addition of genotoxins. Etoposide (Sigma Aldrich, http://www.
signaaldrich.com) and MNNG (Sigma Aldrich) were diluted in culture
media to a concentration of 25 lM and incubated with cells for 3 h.
Following incubation, genotoxin-containing media was removed and
replaced with fresh media with or without thymidine.
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